依托咪酯与氯胺酮用于急诊气管插管:一项随机临床试验
这项前瞻性、随机、开放标签、平行分配、单中心临床试验由美国一家高收治量医疗中心的麻醉气道团队在紧急情况下实施,纳入801例需要急诊气管插管的危重患者,按1:1随机接受依托咪酯(0.2-0.3 mg/kg,n=400)或氯胺酮(1-2 mg/kg,n=401)插管前镇静。主要终点第7天生存率在依托咪酯组显著低于氯胺酮组(77.3% vs 85.1%,差值-7.8,95%CI -13至-2.4,p=0.005);第28天生存率两组无显著差异(依托咪酯64.1% vs 氯胺酮66.8%,差值-2.7,95%CI -9.3至3.9,p=0.294)。结论为氯胺酮组第7天生存率更高,但第28天生存率无显著差异。
要点
- 急诊气管插管危重患者随机接受氯胺酮者第7天生存率85.1%,高于依托咪酯组的77.3%(差值-7.8,95%CI -13至-2.4,p=0.005)。
- 第28天生存率依托咪酯组64.1% vs 氯胺酮组66.8%,差值-2.7(95%CI -9.3至3.9,p=0.294),两组无显著差异。
- 依托咪酯剂量为0.2-0.3 mg/kg,氯胺酮剂量为1-2 mg/kg,均为插管前镇静给药。
- 该试验为单中心、前瞻性、随机、开放标签、平行分配设计,由麻醉气道团队在紧急情况下实施。
- 2015年该院质量改进数据提示危重患者急诊插管时避免依托咪酯与第7天生存获益相关,本试验据此提出假设。
适用人群与场景
- 需要急诊气管插管的危重患者,来自美国一家高收治量医疗中心,由麻醉气道团队在紧急情况下实施插管。
处置流程与药物剂量
- 插管前镇静:依托咪酯0.2-0.3 mg/kg,或氯胺酮1-2 mg/kg,按1:1随机分组给药。
研究设计与关键结果
- 研究类型:前瞻性、随机、开放标签、平行分配、单中心临床试验;纳入801例需要急诊气管插管的危重患者,随机1:1分为依托咪酯组(0.2-0.3 mg/kg,n=400)和氯胺酮组(1-2 mg/kg,n=401)。
- 分析人群:依托咪酯组396例,氯胺酮组395例。
- 主要终点第7天生存率:依托咪酯组77.3% vs 氯胺酮组85.1%,差值-7.8(95%CI -13至-2.4),p=0.005,依托咪酯组显著低于氯胺酮组。
- 次要终点第28天生存率:依托咪酯组64.1% vs 氯胺酮组66.8%,差值-2.7(95%CI -9.3至3.9),p=0.294,两组无显著差异。
证据类型、等级与局限
- 证据类型:前瞻性、随机、开放标签、平行分配、单中心临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管随机接受氯胺酮的患者第7天生存率更高,但第28天生存率无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Etomidate and ketamine are hemodynamically stable induction agents often used to sedate critically ill patients during emergency endotracheal intubation. In 2015, quality improvement data from our hospital suggested a survival benefit at Day 7 from avoidance of etomidate in critically ill patients during emergency intubation. In this clinical trial, we hypothesized that randomization to ketamine instead of etomidate would be associated with Day 7 survival after emergency endotracheal intubation.
METHODS: A prospective, randomized, open-label, parallel assignment, single-center clinical trial performed by an anesthesiology-based Airway Team under emergent circumstances at one high-volume medical center in the United States. 801 critically ill patients requiring emergency intubation were randomly assigned 1:1 by computer-generated, pre-randomized sealed envelopes to receive etomidate (0.2-0.3 mg/kg, n = 400) or ketamine (1-2 mg/kg, n = 401) for sedation prior to intubation. The pre-specified primary endpoint of the trial was Day 7 survival. Secondary endpoints included Day 28 survival.
RESULTS: Of the 801 enrolled patients, 396 were analyzed in the etomidate arm, and 395 in the ketamine arm. Day 7 survival was significantly lower in the etomidate arm than in the ketamine arm (77.3% versus 85.1%, difference - 7.8, 95% confidence interval - 13, - 2.4, p = 0.005). Day 28 survival rates for the two groups were not significantly different (etomidate 64.1%, ketamine 66.8%, difference - 2.7, 95% confidence interval - 9.3, 3.9, p = 0.294).
CONCLUSION: While the primary outcome of Day 7 survival was greater in patients randomized to ketamine, there was no significant difference in survival by Day 28.
参考来源
- Matchett G, Gasanova I, Riccio CA, et al. Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial. Intensive Care Med. 2021. PMID: 34904190. doi:10.1007/s00134-021-06577-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。